Harbour BioMed Holdings Limited ("Harbour BioMed"; Stock Code: 02142.HK) completed its IPO and listing on the Main Board of the Hong Kong Stock Exchange (HKEX) on December 10, 2020, raising approximately HKD 1.711 billion at HKD 12.38 per share. Harbour BioMed is a non-profit, biotechnology company listed under Chapter 18A of the Hong Kong Listing Rules.
Harbour BioMed is a clinical stage, biopharmaceutical company committed to the discovery and development of different antibody therapeutics in the areas of oncology and immunological diseases. To date, the company has developed a diverse and balanced pipeline of more than 10 different drug candidates. The company's key products—Batoclimab (HBM9161), Tanfanercept (HBM9036) and HBM4003–are each under clinical development. The company focuses on developing fully human antibodies based on its patented transgenic mouse platform—Harbour Mice®. Harbour Mice® generates fully human monoclonal antibodies in the classic two heavy and two light chain (H2L2) format, as well as in the heavy chain only (HCAb) format. Building upon our HCAb antibodies, the HCAb-based immune cell engagers (HBICETM) are capable of delivering tumor-killing effects unachievable by combination therapies.
As the Chinese legal adviser to the issuer, Jingtian & Gongcheng's provided one-stop, end-to-end legal services for the IPO and listing of Harbour BioMed, including Chinese legal due diligence, as well as offering Chinese legal opinions and responding to regulatory inquiries.